Article Title: Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting
Authors(s): Saskia Meyer, Maaike Nederend, J.H. Marco Jansen, Karli R. Reiding, Shamir R. Jacobino, Jan Meeldijk, Niels Bovenschen, Manfred Wuhrer, Thomas Valerius, Ruud Ubink, Peter Boross, Gerard Rouwendal, and Jeanette H.W. Leusen
Journal: mAbs
Bibliometrics: Published in 2016, Volume 8, Issue 1, pp. 87–98.
DOI: 10.1080/19420862.2015.1106658.
Publisher: Taylor & Francis
The authors identified an error in the X-axis in the supplementary Figure S1B, the legend and supplemental Material and Methods. We had initially reported that the mice were injected with a single injection of IgA antibody on day 0, directly after tumor inoculation. However, the mice were actually treated on 10 successive days with IgA1 and IgA2 antibody injected intraperitoneally.
The authors apologize for the error. The supplemental Material and Methods section and the figure legend have now been adapted in light of this information, and arrows on the figure indicate the actual treatment regimen.